Role of HSP in the Treatment of Internal Diseases

Akan O. Y., Ortan P., Hosgorler F.

HEAT SHOCK PROTEINS IN NEUROSCIENCE, cilt.20, ss.273-303, 2019 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 20
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1007/978-3-030-24285-5_16
  • Dergi Adı: HEAT SHOCK PROTEINS IN NEUROSCIENCE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED)
  • Sayfa Sayıları: ss.273-303
  • Anahtar Kelimeler: Apoptosis, Cancer therapy, Gastrointestinal disease, Heat shock protein, HSP vaccines, Internal medicine, HEAT-SHOCK-PROTEIN, WATER-IMMERSION STRESS, NITRIC-OXIDE SYNTHASE, GASTRIC-MUCOSAL DEFENSE, HELICOBACTER-PYLORI, TRYPSINOGEN ACTIVATION, ATROPHIC GASTRITIS, ACUTE-PANCREATITIS, INDUCED COLITIS, CELIAC-DISEASE
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Heat shock proteins (HSP) take their name from their apparent accidental discovery following transient heat stress in the salivary glands of Drosophila melanogaster (5 degrees C above normal temperature) HSP. All cells, from bacteria to human, have a common, complicated response to stress that protects them from injury. HSP play a major role in that response. HSP, protect the structure of normal proteins and plays a role in repairing or removing damaged ones. HSP response shows similar effects when faced with stressor conditions, such as oxidative stress, glucose deprivation, and infection, which lead to the misfolding of intracellular proteins. HSP participate in protein prevention from denaturation, repair, degradation of non-repairable ones, cell signal and response formation in the stress situations. Because of their important function in both physiological and pathological fields, it is possible to develop treatment strategies in many areas related to internal medicine. Current Data strongly supports efforts to target HSP in many diseases, mostly oncology. Drugs that make chaperone antagonism, such as Hsp90 inhibitors, reverse the damage caused by overexpressed HSP by helping to break down oncogenes. Treatment with HSP vaccines or HSP antagonists are in phase III trials in both inflammatory diseases and cancer treatment. Further studies will enable it to take its place in the treatment of inflammatory diseases and cancer.